The SERENA study: Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes: a double blind RCT KU Leuven
The incidence of gestational diabetes (GDM) is rising with prevalence rates around 9-12% in Flanders.
GDM is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who
will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women ...